Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$175.30 USD

175.30
398,554

-1.22 (-0.69%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

5-Strong Sell         5

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | A Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for ABMD

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for ABIOMED, Inc. falls in the month of March.

All items in Millions except Per Share data.

3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Assets          
Cash & Equivalents 492 362 230 212 132
Receivables 91 70 54 43 32
Notes Receivable 0 0 0 0 0
Inventories 81 50 35 27 17
Other Current Assets 14 12 8 7 40
Total Current Assets 677 494 327 288 220
Net Property & Equipment 145 117 88 23 9
Investments & Advances 22 38 47 1 14
Other Non-Current Assets 15 17 14 15 15
Deferred Charges 78 71 35 59 45
Intangibles 33 36 31 33 32
Deposits & Other Assets 85 14 8 4 4
Total Assets 1,054 786 550 424 338
Liabilities & Shareholders Equity 3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Notes Payable 0 0 0 0 0
Accounts Payable 32 24 21 9 10
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 1 0 0
Accrued Expenses 57 46 38 28 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 16 15 11 9 7
Total Current Liabilities 106 85 70 47 39
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1 1 1 1 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 16 0 0
Other Non-Current Liabilities 11 11 12 8 7
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 117 97 98 55 47
Shareholders Equity 3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 691 620 566 509 465
Retained Earnings 399 140 -47 -99 -137
Other Equity -15 -4 -21 -15 -17
Treasury Stock 139 67 47 27 19
Total Shareholder's Equity 937 690 452 369 292
Total Liabilities & Shareholder's Equity 1,054 786 550 424 338
Total Common Equity 937 690 452 369 292
Shares Outstanding 45.00 44.20 43.50 42.40 41.10
Book Value Per Share 20.82 15.60 10.39 8.70 7.09

Fiscal Year End for ABIOMED, Inc. falls in the month of March.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents NA 487 492 458 410
Receivables NA 86 91 88 74
Notes Receivable NA 0 0 0 0
Inventories NA 88 81 72 64
Other Current Assets NA 17 14 11 13
Total Current Assets NA 677 677 629 562
Net Property & Equipment NA 152 145 138 134
Investments & Advances NA 40 22 0 0
Other Non-Current Assets NA 15 15 16 16
Deferred Charges NA 67 78 96 116
Intangibles NA 33 33 33 34
Deposits & Other Assets NA 141 85 45 26
Total Assets NA 1,125 1,054 957 887
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable NA 0 0 0 0
Accounts Payable NA 30 32 26 22
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 52 57 52 46
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 19 16 15 14
Total Current Liabilities NA 100 106 93 82
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1 1 1 1
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 11 12 11
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 122 117 106 94
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 705 691 676 660
Retained Earnings NA 488 399 326 281
Other Equity NA -12 -15 -12 -12
Treasury Stock NA 179 139 138 137
Total Shareholder's Equity NA 1,003 937 852 793
Total Liabilities & Shareholder's Equity NA 1,125 1,054 957 887
Total Common Equity 0 1,003 937 852 793
Shares Outstanding 45.30 45.30 45.00 45.00 45.00
Book Value Per Share 0.00 22.13 20.82 18.92 17.62